The Life Sciences Report
For news on how catalysts affect specific stocks, read the updated Life Sciences Report Watchlist.
Notable Quotes
"By the end of 2014, you're going to have some pretty good news flow out of BDSI." (4/24/14) BioDelivery Sciences International Inc. - Charles Duncan, Piper Jaffray & Co. More >
"ARNI's onapristone could legitimately be considered a pipeline in a single product." (4/22/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More >
"THLD's soft-tissue sarcoma study should read out at the end of 2015; that could be a very exciting time." (4/24/14) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan More >
"CUR's science is cutting edge, and of a very high quality." (4/22/14) Neuralstem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More >
"The Phase 2 trial for VGX-3100 could be a major clinical validation of the power of INO's broadly applicable platform." (4/24/14) Inovio Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >
The Approval Process in Action
Source: The Life Sciences Report and Visual Capitalist (5/1/13)
What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.
More Experts
"DMPI's VAL-083 is a first-in-class small-molecule chemotherapeutic." (4/17/14) DelMar Pharmaceuticals Inc. - The Life Sciences Report Interview with Grant Zeng More >
"There is great potential for NEO to grow in the future." (4/17/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Grant Zeng More >
"SNGX has a very diversified pipeline under development; its Phase 2 trial for SGX924 is going very well." (4/17/14) Soligenix Inc. - The Life Sciences Report Interview with Grant Zeng More >
"RXII has some very important valuation-driving events in progress." (4/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Keith Markey More >
"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation." (4/3/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum More >